A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP

Hyo Jin Son, Ji Ae Lee, Nari Shin, Ji Hyun Choi, Jai Seo, Dae Yoon Chi, Cheol Soon Lee, Eun Mee Kim, Han Choe, Onyou Hwang

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE In Parkinson's disease, the dopaminergic neurones in the substantia nigra undergo degeneration. While the exact mechanism for the degeneration is not completely understood, neuronal apoptosis and neuroinflammation are thought to be key contributors. We have recently established that MMP-3 plays crucial roles in dopaminergic cell death and microglial activation. EXPERIMENTAL APPROACH We tested the effects of 7-hydroxy-6-methoxy-2-propionyl-1,2,3,4-tetrahydroisoquinoline (PTIQ) on expression of MMP-3 and inflammatory molecules and dopaminergic cell death in vitro and in an animal model of Parkinson's disease, and Parkinson's disease-related motor deficits. The pharmacokinetic profile of PTIQ was also evaluated. KEY RESULTS PTIQ effectively suppressed the production of MMP-3 induced in response to cellular stress in the dopaminergic CATH.a cell line and prevented the resulting cell death. In BV-2 microglial cells activated with lipopolysaccharide, PTIQ down-regulated expression of MMP-3 along with IL-1β, TNF-α and cyclooxygenase-2 and blocked nuclear translocation of NF-κB. In the mouse model of Parkinson's disease,induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), PTIQ attenuated the associated motor deficits, prevented neurodegeneration and suppressed microglial activation in the substantia nigra. Pharmacokinetic analysis showed it was relatively stable against liver microsomal enzymes, did not inhibit the cytochrome p450 isozymes or the hERG ion channel, exhibited no cytotoxicity on liver cells or lethality when administered at 1000 mg kg -1 and entered the brain rather rapidly yielding a 28% brain:plasma ratio after i.p. injection. CONCLUSIONS AND IMPLICATIONS These results suggest PTIQ has potential as a candidate drug for disease-modifying therapy for Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)2213-2227
Number of pages15
JournalBritish Journal of Pharmacology
Volume165
Issue number7
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Dopaminergic Neurons
Substantia Nigra
Parkinson Disease
Animal Models
Matrix Metalloproteinases
Cell Death
Pharmacokinetics
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Liver
Brain
Cyclooxygenase 2
Interleukin-1
Ion Channels
Cytochrome P-450 Enzyme System
Isoenzymes
Lipopolysaccharides
4-phenyl-1,2,3,6-tetrahydropyridine
1,2,3,4-tetrahydroisoquinoline
Apoptosis
Cell Line

Keywords

  • dopaminergic neuron
  • microglia
  • MMP-3
  • MPTP
  • Parkinson's disease
  • pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology

Cite this

A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP. / Son, Hyo Jin; Lee, Ji Ae; Shin, Nari; Choi, Ji Hyun; Seo, Jai; Chi, Dae Yoon; Lee, Cheol Soon; Kim, Eun Mee; Choe, Han; Hwang, Onyou.

In: British Journal of Pharmacology, Vol. 165, No. 7, 01.04.2012, p. 2213-2227.

Research output: Contribution to journalArticle

Son, Hyo Jin ; Lee, Ji Ae ; Shin, Nari ; Choi, Ji Hyun ; Seo, Jai ; Chi, Dae Yoon ; Lee, Cheol Soon ; Kim, Eun Mee ; Choe, Han ; Hwang, Onyou. / A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP. In: British Journal of Pharmacology. 2012 ; Vol. 165, No. 7. pp. 2213-2227.
@article{7538e560773f418e982b8b1f90e12628,
title = "A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP",
abstract = "BACKGROUND AND PURPOSE In Parkinson's disease, the dopaminergic neurones in the substantia nigra undergo degeneration. While the exact mechanism for the degeneration is not completely understood, neuronal apoptosis and neuroinflammation are thought to be key contributors. We have recently established that MMP-3 plays crucial roles in dopaminergic cell death and microglial activation. EXPERIMENTAL APPROACH We tested the effects of 7-hydroxy-6-methoxy-2-propionyl-1,2,3,4-tetrahydroisoquinoline (PTIQ) on expression of MMP-3 and inflammatory molecules and dopaminergic cell death in vitro and in an animal model of Parkinson's disease, and Parkinson's disease-related motor deficits. The pharmacokinetic profile of PTIQ was also evaluated. KEY RESULTS PTIQ effectively suppressed the production of MMP-3 induced in response to cellular stress in the dopaminergic CATH.a cell line and prevented the resulting cell death. In BV-2 microglial cells activated with lipopolysaccharide, PTIQ down-regulated expression of MMP-3 along with IL-1β, TNF-α and cyclooxygenase-2 and blocked nuclear translocation of NF-κB. In the mouse model of Parkinson's disease,induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), PTIQ attenuated the associated motor deficits, prevented neurodegeneration and suppressed microglial activation in the substantia nigra. Pharmacokinetic analysis showed it was relatively stable against liver microsomal enzymes, did not inhibit the cytochrome p450 isozymes or the hERG ion channel, exhibited no cytotoxicity on liver cells or lethality when administered at 1000 mg kg -1 and entered the brain rather rapidly yielding a 28{\%} brain:plasma ratio after i.p. injection. CONCLUSIONS AND IMPLICATIONS These results suggest PTIQ has potential as a candidate drug for disease-modifying therapy for Parkinson's disease.",
keywords = "dopaminergic neuron, microglia, MMP-3, MPTP, Parkinson's disease, pharmacokinetics",
author = "Son, {Hyo Jin} and Lee, {Ji Ae} and Nari Shin and Choi, {Ji Hyun} and Jai Seo and Chi, {Dae Yoon} and Lee, {Cheol Soon} and Kim, {Eun Mee} and Han Choe and Onyou Hwang",
year = "2012",
month = "4",
day = "1",
doi = "10.1111/j.1476-5381.2011.01692.x",
language = "English (US)",
volume = "165",
pages = "2213--2227",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP

AU - Son, Hyo Jin

AU - Lee, Ji Ae

AU - Shin, Nari

AU - Choi, Ji Hyun

AU - Seo, Jai

AU - Chi, Dae Yoon

AU - Lee, Cheol Soon

AU - Kim, Eun Mee

AU - Choe, Han

AU - Hwang, Onyou

PY - 2012/4/1

Y1 - 2012/4/1

N2 - BACKGROUND AND PURPOSE In Parkinson's disease, the dopaminergic neurones in the substantia nigra undergo degeneration. While the exact mechanism for the degeneration is not completely understood, neuronal apoptosis and neuroinflammation are thought to be key contributors. We have recently established that MMP-3 plays crucial roles in dopaminergic cell death and microglial activation. EXPERIMENTAL APPROACH We tested the effects of 7-hydroxy-6-methoxy-2-propionyl-1,2,3,4-tetrahydroisoquinoline (PTIQ) on expression of MMP-3 and inflammatory molecules and dopaminergic cell death in vitro and in an animal model of Parkinson's disease, and Parkinson's disease-related motor deficits. The pharmacokinetic profile of PTIQ was also evaluated. KEY RESULTS PTIQ effectively suppressed the production of MMP-3 induced in response to cellular stress in the dopaminergic CATH.a cell line and prevented the resulting cell death. In BV-2 microglial cells activated with lipopolysaccharide, PTIQ down-regulated expression of MMP-3 along with IL-1β, TNF-α and cyclooxygenase-2 and blocked nuclear translocation of NF-κB. In the mouse model of Parkinson's disease,induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), PTIQ attenuated the associated motor deficits, prevented neurodegeneration and suppressed microglial activation in the substantia nigra. Pharmacokinetic analysis showed it was relatively stable against liver microsomal enzymes, did not inhibit the cytochrome p450 isozymes or the hERG ion channel, exhibited no cytotoxicity on liver cells or lethality when administered at 1000 mg kg -1 and entered the brain rather rapidly yielding a 28% brain:plasma ratio after i.p. injection. CONCLUSIONS AND IMPLICATIONS These results suggest PTIQ has potential as a candidate drug for disease-modifying therapy for Parkinson's disease.

AB - BACKGROUND AND PURPOSE In Parkinson's disease, the dopaminergic neurones in the substantia nigra undergo degeneration. While the exact mechanism for the degeneration is not completely understood, neuronal apoptosis and neuroinflammation are thought to be key contributors. We have recently established that MMP-3 plays crucial roles in dopaminergic cell death and microglial activation. EXPERIMENTAL APPROACH We tested the effects of 7-hydroxy-6-methoxy-2-propionyl-1,2,3,4-tetrahydroisoquinoline (PTIQ) on expression of MMP-3 and inflammatory molecules and dopaminergic cell death in vitro and in an animal model of Parkinson's disease, and Parkinson's disease-related motor deficits. The pharmacokinetic profile of PTIQ was also evaluated. KEY RESULTS PTIQ effectively suppressed the production of MMP-3 induced in response to cellular stress in the dopaminergic CATH.a cell line and prevented the resulting cell death. In BV-2 microglial cells activated with lipopolysaccharide, PTIQ down-regulated expression of MMP-3 along with IL-1β, TNF-α and cyclooxygenase-2 and blocked nuclear translocation of NF-κB. In the mouse model of Parkinson's disease,induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), PTIQ attenuated the associated motor deficits, prevented neurodegeneration and suppressed microglial activation in the substantia nigra. Pharmacokinetic analysis showed it was relatively stable against liver microsomal enzymes, did not inhibit the cytochrome p450 isozymes or the hERG ion channel, exhibited no cytotoxicity on liver cells or lethality when administered at 1000 mg kg -1 and entered the brain rather rapidly yielding a 28% brain:plasma ratio after i.p. injection. CONCLUSIONS AND IMPLICATIONS These results suggest PTIQ has potential as a candidate drug for disease-modifying therapy for Parkinson's disease.

KW - dopaminergic neuron

KW - microglia

KW - MMP-3

KW - MPTP

KW - Parkinson's disease

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84863248744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863248744&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2011.01692.x

DO - 10.1111/j.1476-5381.2011.01692.x

M3 - Article

C2 - 21951056

AN - SCOPUS:84863248744

VL - 165

SP - 2213

EP - 2227

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 7

ER -